Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.

Published in: Annals of the rheumatic diseases (2020)

Compared with colchicine, allopurinol and febuxostat similarly increased the risk of HSRs. Allopurinol and febuxostat did not differ from each other. In allopurinol users, starting dose, female sex and diabetes increased this risk, findings that need further study.

Keyphrases

type diabetes
cardiovascular disease
health insurance
electronic health record
healthcare
big data
glycemic control
metabolic syndrome
affordable care act